Related Experiment Videos
Advances in immunotherapy of hematologic malignancies
1Clinical Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98104, USA.
Current Opinion in Hematology
|September 25, 1998
Summary
Monoclonal antibodies like rituximab show promise in treating B-cell non-Hodgkin
Area of Science:
- Hematology and Oncology
- Immunotherapy
- Cancer Biology
Background:
- B-cell non-Hodgkin's lymphoma (NHL), follicular NHL, chronic lymphocytic leukemia (CLL), and acute myeloid leukemia (AML) are significant hematologic malignancies.
- Monoclonal antibodies (mAbs) targeting specific cell surface antigens have emerged as a key therapeutic strategy in hematologic cancers.
- Existing treatments for these conditions have limitations, necessitating the exploration of novel therapeutic approaches.
Purpose of the Study:
- To review the efficacy of various monoclonal antibody-based therapies in B-cell NHL, CLL, and AML.
- To discuss the potential role of idiotype vaccination in preventing relapse in follicular NHL.
- To explore the application of adoptive cellular therapy and gene-modified lymphocytes in managing hematologic malignancies and their complications.
Main Methods:
- Review of existing literature on monoclonal antibody therapies, including chimeric, radiolabeled, and conjugated forms.
- Analysis of studies investigating idiotype vaccination for follicular NHL.
- Examination of data on adoptive cellular therapy and suicide gene therapy for hematologic disorders and graft-versus-host disease.
Main Results:
- Chimeric anti-CD20 antibody rituximab and radiolabeled anti-CD20 mAbs demonstrate significant activity in B-cell NHL.
- Idiotype vaccination shows potential for relapse prevention in follicular NHL.
- Campath-1H (anti-CD52) is active in CLL; anti-CD45 and anti-CD33 mAbs show activity in AML. Adoptive cellular therapy is effective against posttransplantation relapse and lymphoproliferative disorders.
Conclusions:
- Monoclonal antibody-based therapies are effective against various B-cell and myeloid leukemias and lymphomas.
- Idiotype vaccination represents a promising strategy for maintaining remission in follicular NHL.
- Adoptive cellular therapy and suicide gene therapy offer therapeutic options for complex hematologic conditions and transplant-related complications.